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OBJECTIVES The joint predictive value of lipid and C-reactive protein (CRP) levels, as well as a possible
interaction between statin therapy and CRP, were evaluated for survival after angiographic
diagnosis of coronary artery disease (CAD).
BACKGROUND Hyperlipidemia increases risk of CAD and myocardial infarction. For first myocardial
infarction, the combination of lipid and CRP levels may be prognostically more powerful.
Although lipid levels are often measured at angiography to guide therapy, their prognostic
value is unclear.
METHODS Blood samples were collected from a prospective cohort of 985 patients diagnosed angio-
graphically with severe CAD (stenosis $ 70%) and tested for total cholesterol (TC),
low-density lipoprotein (LDL), high-density lipoprotein (HDL), and CRP levels. Key risk
factors, including initiation of statin therapy, were recorded, and subjects were followed for
an average of 3.0 years (range: 1.8 to 4.3 years) to assess survival.
RESULTS Mortality was confirmed for 109 subjects (11%). In multiple variable Cox regression, levels of
TC, LDL, HDL and the TC:HDL ratio did not predict survival, but statin therapy was
protective (adjusted hazard ratio [HR] 5 0.49, p 5 0.04). C-reactive protein levels, age, left
ventricular ejection fraction and diabetes were also independently predictive. Statins primarily
benefited subjects with elevated CRP by eliminating the increased mortality across increasing
CRP tertiles (statins: HR 5 0.97 per tertile, p-trend 5 0.94; no statins: HR 5 1.8 per tertile,
p-trend , 0.0001).
CONCLUSIONS Lipid levels drawn at angiography were not predictive of survival in this population, but
initiation of statin therapy was associated with improved survival regardless of the lipid levels.
The benefit of statin therapy occurred primarily in patients with elevated CRP. (J Am Coll
Cardiol 2000;36:1774–80) © 2000 by the American College of Cardiology
Atherosclerotic cardiovascular disease accounts for nearly
half of the deaths in the American population (1). Coronary
artery disease (CAD) is responsible for the majority of these
deaths. Major established risk factors for the development
of CAD include hyperlipidemia, hypertension, smoking,
diabetes and a family history of CAD (2,3). Some consider
hyperlipidemia to be the most significant modifiable exam-
ple of these risk factors (4).
Other factors such as inflammation have recently been
linked to the risk of CAD. The inflammatory marker
C-reactive protein (CRP) has been strongly associated with
CAD, coronary ischemia and myocardial infarction (MI)
(5–9). Recently, Ridker et al. (10) reported that, taken
together, CRP and lipid levels provided a more useful
prognostic marker for the assessment of primary CAD risk.
This may suggest a connection between hyperlipidemia and
inflammation in the pathogenesis of CAD.
Statins, or 3-hydroxy-3-methylglutaryl coenzyme A re-
ductase inhibitors, are a class of medications that primarily
block mevalonate synthesis, resulting in positive effects on
lipid parameters, especially low-density lipoprotein choles-
terol (LDL). Clinical trials demonstrate that statins are safe
and effective in treating hyperlipidemia and reducing car-
diovascular events (11–15). Statins have also been reported
to produce nonlipid-lowering benefits, including anti-
thrombotic and anti-inflammatory effects (16,17). However,
potential interactions between statin therapy, hyperlipid-
emia and inflammation in patients with preexisting CAD
are unknown.
The purpose of this study was to prospectively evaluate
the combined predictive value of lipid and CRP levels on
survival among patients with angiographically-defined se-
vere CAD. A second objective was to determine whether
statin therapy affected survival for patients with and without
elevated CRP.
METHODS
Study population. Between August 15, 1994, and Febru-
ary 28, 1997, 1,707 consecutive patients undergoing coro-
nary arteriography at the LDS Hospital (Salt Lake City,
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Utah) were enrolled in a cardiovascular registry (the Inter-
mountain Heart Study). Patients were of unrestricted age
and gender and gave written informed consent for a blood
draw at angiography for use in confidential studies approved
by the hospital’s institutional review board. In general,
patients were residents of Utah, southwestern Idaho or
southeastern Wyoming, a population that is primarily of
British and Northern European descent. Of these, 985 were
found to have severe CAD as defined by one or more $70%
stenosis in $1 coronary artery or a primary branch, and
these 985 were included in this study.
Follow-up and determination of subject outcomes. Sub-
jects were followed-up until death or until December 1998.
They (or family members, in the case of subject death or
disability) were interviewed by telephone survey. Deaths
were verified through a national Social Security death index.
Subjects unavailable by telephone but not listed in the death
index were considered to be alive, thus allowing for 100%
assessment of survival.
Determination of lipid levels. Lipid panels were evaluated
by assay on a Vitros 950 (Johnson & Johnson Clinical
Diagnostics, Rochester, New York), which measures total
cholesterol (TC), triglyceride and high-density lipoprotein
(HDL) levels by enzymatic methods and LDL calculated
from these. The TC:HDL ratio was computed by dividing
TC by the corresponding HDL level.
Determination of CRP. Testing for CRP was performed
using a fluorescence polarization immunoassay (Abbott
Diagnostics, Abbott Park, Illinois). Assay validation showed
that 95% of healthy individuals had CRP levels ,0.5 mg/dl,
and 98% had levels ,1.0 mg/dl (Abbott Diagnostics, List
No. 9550, January 1996). The between-run coefficient of
variation of this assay was 4.3% and 2.2% at mean levels of
1.10 mg/dl and 2.94 mg/dl, respectively. For analysis, CRP
levels were divided into three tertiles of equal sample size.
Assessment of statin prescription. Prescription of statins
at the time of hospital discharge was determined from a
hospital-wide clinical database (18). The database query
asked for the prescription of any of the following agents:
simvastatin, pravastatin, atorvastatin, lovastatin or fluva-
statin. Statin use before hospitalization was not known, and
long-term compliance with therapy was not determined.
Statin prescription status was available for 889 study sub-
jects; the other 96 were excluded from the statin analysis.
Other variables examined. Subject demographics, tradi-
tional medical risk factors and clinical variables were eval-
uated to control for confounding factors. These included
age, sex, diabetes mellitus, hypertension, smoking, family
history of CAD, presenting diagnosis, clinical interventions,
number of diseased coronary vessels, renal failure and
left ventricular ejection fraction (LVEF). Diabetes was
diagnosed by a history of fasting blood sugar greater than
126 mg/dl or a glycosylated hemoglobin .7.5%. Hyperten-
sion was defined as a history of a systolic blood pressure
.160 mm Hg or a diastolic blood pressure .90 mm Hg.
Family history was considered positive if a first-order
relative had suffered cardiovascular death, MI or coronary
revascularization before age 65. Tobacco use was considered
present for active smokers or those with a history of .10
pack-years. The clinical presentation at hospitalization in-
cluded stable angina (stable exertional symptoms only),
unstable angina (progressive symptoms or symptoms at rest)
or MI (creatine kinase-MB .6 mg/dl and creatine
kinase-MB index .3%). Clinical treatment at hospitaliza-
tion was categorized as medical therapy (only), percutaneous
coronary interventions (including balloon angioplasty,
atherectomy or stenting) and coronary artery bypass surgery
(CABG). Renal failure was regarded as present if serum
creatinine was $2.0 mg/dl.
Statistical considerations. Survival analysis evaluated the
proportional hazards for mortality by Cox regression. The
chi-square approximation to the likelihood ratio test was
used to examine whether a univariate association with
mortality existed for each known or potential risk factor.
Subject age, LVEF (generally by contrast ventriculography
or by echocardiogram if unavailable) and levels of TC,
HDL, LDL and the TC:HDL were entered as continuous
variables. C-reactive protein was evaluated as a categorical
variable, comparing the third or second tertile to the first.
Multiple variable Cox regression (SPSS, v9.0) was uti-
lized to determine hazard ratios (HR) corrected for possible
confounding. The regression model was built by evaluation
for significant or near-significant factors (p , 0.10) and for
factors confounding those associations. Hazard ratios and
95% confidence intervals (CI) are presented along with
two-tailed p values, designating a p value of 0.05 as
nominally significant.
RESULTS
Patient characteristics. Table 1 summarizes the overall
baseline subject characteristics by statin prescription. Those
given statins were younger and more frequently treated with
revascularization. The distribution of statin use among the
study cohort was 63% simvastatin, 15% atorvastatin, 13%
pravastatin, 5% lovastatin and 4% fluvastatin.
Overall, the prevalence of standard cardiovascular risk
factors was similar to other populations with known CAD.
Table 2 provides the average levels of TC, LDL, HDL, the
TC:HDL ratio and CRP. Despite that statins are typically
Abbreviations and Acronyms
CAD 5 coronary artery disease
CI 5 95% confidence interval
CRP 5 C-reactive protein
HDL 5 high-density lipoprotein
HR 5 hazard ratio
LDL 5 low-density lipoprotein
LVEF 5 left ventricular ejection fraction
MI 5 myocardial infarction
TC 5 total cholesterol
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prescribed based on TC and LDL, these were similarly
distributed in the statins (ranges: TC 5 83 to 445 mg/dl;
LDL 5 26 to 322 mg/dl) and nonstatins groups (ranges:
TC 5 85 to 324 mg/dl; LDL5 23 to 269 mg/dl). The
tertiles of CRP were: 1) ,1.2 mg/dl, 2) 1.2 to 1.7 mg/dl and
3) .1.7 mg/dl. During the follow-up period (mean: 3.0
years, range: 1.8 to 4.3 years), death was confirmed for 109
subjects (11%).
Prediction of survival. Univariate Cox analyses revealed
no association with survival for levels of TC (p 5 0.19),
LDL (p 5 0.30), HDL (p 5 0.051) or TC:HDL ratio (p 5
0.99). Statin prescription, however, was associated with
greatly improved survival (HR 5 0.39; CI 5 [0.20, 0.78],
p 5 0.002) (Fig. 1). Survival for statin-treated subjects was
95% after an average follow-up of 1,100 days, compared
with 87% for those without statins. Other univariate pre-
dictors of survival included age, LVEF, diabetes and CRP
levels (Table 3).
Multiple variable Cox regression was used to adjust the
univariate associations of statins and CRP for other signif-
icant or confounding factors. Patient age and index treat-
ments were significantly different based on statin prescrip-
tion status (Table 1), suggesting possible confounding. In
bivariate Cox regression, however, index treatment did not
confound statins; this was also found in multiple variable
analysis controlling for treatment, statins and other signif-
icant factors. In contrast, analysis showed that age some-
what reduced the association of statins with survival; how-
ever, statins did retain a significant independent effect.
Additionally, although interventional treatment, smoking
and number of diseased vessels were each significant uni-
variate predictors of survival, those preliminary associations
were eliminated in multiple variable analysis by patient age
and LVEF. Levels of TC, LDL, HDL and the TC:HDL
ratio remained nonsignificant in multiple variable analysis.
The final regression model included statin prescription
(HR 5 0.49, CI 5 [0.24, 0.97], p 5 0.04) age, LVEF,
CRP and diabetes (Table 4).
Statins and CRP. The predictive value of CRP depended
on the status of statin therapy (Fig. 2). For patients not
prescribed statins, increasing CRP levels were associated
with a graded and markedly increased risk of mortality (test
of trend: HR 5 1.8 per tertile, p , 0.0001). In contrast,
among the statin group this association was eliminated such
that patients had similar survival regardless of CRP level
(HR 5 0.98 per tertile, p 5 0.97). These results were
unchanged by multiple variable analysis (no statins: HR 5
1.8 per tertile, CI 5 [1.3, 2.3], p , 0.0001; statins: HR 5
0.97 per tertile, p 5 0.94).
Table 1. Baseline Characteristics of the Study Population Including Percent of Subjects
Receiving Prescription of Statins at Hospital Discharge
Risk Factor (n 5 889) Overall (n) Statins No Statin p Value*
Statin therapy 19% (172) 19% 81% —
Demographics
Age (mean years 6 SD) 65 6 11 63 6 10 66 6 11 0.007
Gender (males) 77% (683) 71% 78% 0.06
Clinical presentation
Stable angina 44% (393) 45% 44% NS
Unstable angina 32% (285) 32% 32% NS
Acute MI 24% (211) 23% 24% NS
Coronary anatomy
Single-vessel 35% (309) 29% 36% 0.09
Double-vessel 30% (265) 32% 29% NS
Triple-vessel 35% (315) 39% 35% NS
Treatment at index hospitalization
Medical therapy only 44% (389) 29% 47% ,0.001
PCI 23% (209) 30% 22% 0.06
CABG 33% (291) 41% 30% 0.008
Cardiovascular risk factors
Diabetes 19% (165) 20% 18% NS
Family history 33% (291) 36% 32% NS
Hypertension 53% (468) 53% 53% NS
LVEF (mean 6 SD) 60 6 16% 60 6 17% 60 6 17% NS
Renal failure 8% (69) 6% 8% NS
Smoking 28% (249) 25% 29% NS
*Statin vs. no statin.
CABG 5 coronary artery bypass graft; LVEF 5 left ventricular ejection fraction; MI 5 myocardial infarction; PCI 5
percutaneous coronary intervention; SD 5 standard deviation.
Table 2. Baseline Laboratory Values Measured at the
Index Angiogram
Risk Factor







TC (mg/dl) 181 6 44 182 6 50 181 6 42 NS
LDL (mg/dl) 120 6 38 117 6 43 120 6 37 NS
HDL (mg/dl) 34 6 14 34 6 14 33 6 14 NS
TC:HDL ratio (mg/dl) 6.6 6 5.4 6.4 6 5.4 6.6 6 5.4 NS
CRP (mg/dl) 2.3 6 2.5 2.2 6 2.2 2.3 6 2.6 NS
CRP 5 C-reactive protein; HDL 5 high-density lipoprotein cholesterol; LDL 5
low-density lipoprotein cholesterol; SD 5 standard deviation; TC 5 total cholesterol.
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These differences in CRP-related survival are also illus-
trated by comparisons of statin status within individual
CRP tertiles although the within-tertile comparisons were
not statistically significant. Statins reduced death in the
third tertile from 18.5% in the nonstatin group to 4.6% in
the statin group (adjusted HR 5 0.26, CI 5 [0.06,1.08],
p 5 0.06). Statins reduced death in the second tertile from
14.9% to 6.3% (adjusted HR 5 0.65, p 5 0.42) and in the
first tertile from 5.8% to 4.9% (adjusted HR 5 1.04, p 5
0.96).
DISCUSSION
Summary of study findings. Lipid levels, including levels
of TC, LDL, HDL and the TC:HDL ratio, did not predict
mortality after angiographic CAD diagnosis in this popu-
lation. As a result joint analysis of CRP and lipid levels was
not prognostically useful for secondary risk assessment
although its usefulness has been reported for prediction of
first MI (10). The cholesterol-lowering statin agents, how-
ever, were found to be associated with reduced mortality.
Analysis of statin prescription and levels of the inflamma-
tory marker, CRP, showed that the clinical benefit of statin
treatment was contained primarily in those patients with
elevated CRP.
Cholesterol levels and cardiovascular risk. Cholesterol
level is a major risk factor for the primary development of
clinical CAD (2,3) and perhaps the most important among
the traditional risk factors (4). Data regarding lipid levels
and the prediction of cardiovascular events after the diag-
nosis of CAD are sparse, but, given the risk associated with
lipid levels and the development of CAD, further investi-
gation of the CAD risk after diagnosis is warranted.
Although lipid levels did not predict mortality in this or
other secondary prevention studies (19,20), this does not
contradict the wealth of data supporting cholesterol as a risk
factor for primary development of CAD. Several possible
explanations exist. First, our results may suggest that high
cholesterol levels do not increase the risk of death once
CAD has developed. Death after the establishment of
disease may involve different (acute phase) mechanisms that
do not depend heavily on processes influenced by lipid
Figure 1. Kaplan-Meier survival curve showing the cumulative survival
according to statin prescription. In contrast with the findings of the 4S
trial, the curve separation occurred between 30 and 40 days after statin
prescription. Solid line 5 statins; dashed line 5 no statins.
Table 3. Death Rate and Univariate Significance for the Various
Risk Factors
Risk Factor Death Rate p Value
C-reactive protein
1st tertile 5% (reference)
2nd tertile 13% 0.0009
3rd tertile 15% 0.0001
Age






Stable angina 12% (reference)
Unstable angina 9% NS





Treatment at index hospitalization





















CABG 5 coronary artery bypass graft; LVEF 5 left ventricular ejection fraction;
MI 5 myocardial infarction; PCI 5 percutaneous coronary intervention.
Table 4. Final Multiple Variable Cox Regression Model
Showing the Independent Protective Effect of Statins
Risk Factor (n 5 889) Hazard Ratio CI p Value
Age 1.08 per year 1.05, 1.10 ,0.0001
LVEF 0.97 per % increase 0.96, 0.99 ,0.0001
CRP 1.6 per tertile 1.3, 2.1 0.0002
Diabetes 1.7 1.1, 2.6 0.02
Statins 0.49 0.24, 0.97 0.04
CI 5 95% confidence interval; CRP 5 C-reactive protein; LVEF 5 left ventricular
ejection fraction.
Lipid levels, including total cholesterol, low-density lipoprotein cholesterol and
high-density lipoprotein cholesterol, were not predictive of long-term death in this
model.
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levels. Second, once a patient has developed CAD, the lack
of association for lipids may indicate that the lipid levels are
too high for that particular patient, regardless of whether
the absolute lipid levels are above what might be considered
a typical at-risk level. If so, lipid-lowering treatment may be
warranted. Finally, statins may work through mechanisms
unrelated or only indirectly dependent on lowering of
plasma lipid levels (i.e., anti-inflammatory effects, lowering
of plaque oxidized-LDL, etc.).
Statins and risk. In multiple clinical trials of cholesterol
reduction and event prevention using statin agents, lowering
of LDL levels has been shown to protect against first MI,
subsequent MI and cardiovascular-related mortality. Several
studies found that, in patients with known CAD, statin use
decreased the risk of subsequent mortality and coronary
events (11,12). Other randomized studies of statins found
that patients with average or “normal” lipid levels also
benefit from statin use (13–15). Additional evidence indi-
cates that statins slow the progression of CAD in addition
to reducing coronary events (21,22).
In this study, among patients with a wide range of lipid
levels and with angiographic evidence for CAD, statin
prescription was protective against future mortality. This
finding is consistent with the randomized clinical trials.
Such a benefit, even among patients with “normal” lipid
levels, may indicate that a percentage reduction in lipid
levels should be the goal for patients after diagnosis, not an
absolute reduction from “abnormal” to “normal” levels
(23,24).
In addition, it has been proposed that statins may
produce beneficial effects other than through their direct
plasma lipid-lowering capability (16,17). These benefits
may include inhibition of vascular smooth muscle cell
proliferation (25–27), prevention of thromboembolism (28–
30), improvement of endothelial function (27,31–33) and
alteration of the immune (inflammatory) response (16,34).
Reduction in plaque oxidized LDL may also be a mecha-
nism of benefit and may be poorly reflected by circulating
lipid levels. These proposals are supported by the positive
benefit of statins that was found in our study, and this
benefit appears regardless of baseline lipid levels.
Interestingly, and in contrast with the findings of the 4S
trial (11), the separation in the survival curve began quickly
—between 30 and 40 days after initiation of statin therapy.
This finding requires further evaluation.
Statins and CRP. Plasma CRP, a nonspecific marker of
inflammation, has received much attention as a predictor of
risk. Ridker et al. (5) showed it to predict cardiovascular
events in a prospective study of presumably healthy physi-
cians. We have found CRP to be associated with CAD and
a history of MI and also with mortality after CAD diagnosis
in large, angiographically-defined populations (9,35). Rid-
ker et al. (19) have reported results from a retrospective
substudy of the CARE trial that are consistent with the
findings of our present study. In the CARE trial, patients
with elevated CRP at baseline who were randomized to
pravastatin experienced a greater reduction in MI or mor-
tality compared with placebo than did those with nonel-
evated baseline CRP levels.
Our larger, prospective observational study of patients
who were angiographically diagnosed with severe CAD
confirms the results of the CARE study. Together, they
indicate that statins are more beneficial for patients with
elevated CRP than in those whose CRP is normal at
baseline. Moreover, the reduction in cardiovascular risk due
to statins for patients with high CRP may be the result of an
actual lowering of CRP levels (30,36,37).
Study strengths and limitations. This study was a pro-
spective, but observational, evaluation of mortality. The
failure to randomize to statins or to use a single statin agent
limited the ability of the study to discern between possible
differences in the effects of the various statin agents. In
addition, the actual statin doses and the patient compliance
with therapy were not known. However, inadequate dosing
and noncompliance would bias the outcome in favor of the
null hypothesis. The benefits found in this study, which are
attributed to statins, could be confounded by, or due in part
to, selection biases associated with statin use. However,
potential confounders were adjusted for by multiple variable
Cox regression, including baseline lipid levels and clinical
treatment, and the effect of statins remained independently
significant.
The use of statins before hospitalization was also not
known. This may have produced a bias toward greater
significance for statin therapy by predisposing the statin
group to a relatively lesser severity of disease. Because statin
prescription has not been based on CRP levels in the past,
however, the association of CRP and statins to mortality
may not be affected.
Baseline CRP levels might have been influenced by
myocardial injury (due to MI). However, the presenting
clinical status was controlled in the multiple variable analysis
Figure 2. Percent mortality for statin prescription stratified by CRP levels.
For patients receiving statins the risk due to increasing CRP was elimi-
nated. In contrast, among those not prescribed statins, a significant trend
toward higher mortality existed across increasing CRP tertiles. CRP 5
C-reactive protein.
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and did not alter the overall association of CRP to mortality.
Additionally, CRP has been measured by various methods
in the literature. We analyzed CRP by tertiles instead of an
actual concentration, and, thus, the results are unlikely to
relate to the specific CRP measurement method.
The unrandomized, observational nature of this study
may be considered to be a strength. This study utilized a
design that better approximates real-world actual use in
which drug assignment is not randomized, compliance with
therapy is not tracked, and patients are not excluded from
therapy due to solely study-based criteria. Each of these
points increases the generalizability of this study’s results to
the overall CAD patient population. At the same time,
though, the results also confirm a similar study completed
among a randomized study population.
Conclusions. This study suggests four possible conclu-
sions: 1) although lipid levels are useful in primary preven-
tion, they are not predictive of death when drawn at the
time of angiographic CAD diagnosis; 2) prescription of
statins for patients who have a broad range of lipid levels
and are newly diagnosed with CAD is associated with a
reduction in mortality; 3) CRP is a strong predictor of
mortality in patients with CAD, as previously described;
and 4) statin therapy is particularly beneficial in patients
with angiographically-severe CAD whose CRP level is
relatively elevated and, thus, statins may exert an anti-
inflammatory effect on atherosclerosis.
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